AU2019237413C1 - Recombinant virus capable of stably expressing target proteins - Google Patents

Recombinant virus capable of stably expressing target proteins

Info

Publication number
AU2019237413C1
AU2019237413C1 AU2019237413A AU2019237413A AU2019237413C1 AU 2019237413 C1 AU2019237413 C1 AU 2019237413C1 AU 2019237413 A AU2019237413 A AU 2019237413A AU 2019237413 A AU2019237413 A AU 2019237413A AU 2019237413 C1 AU2019237413 C1 AU 2019237413C1
Authority
AU
Australia
Prior art keywords
gene
polynucleotide
recombinant virus
virus
ehv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019237413A
Other languages
English (en)
Other versions
AU2019237413B2 (en
AU2019237413A1 (en
Inventor
Guanggang MA
Sen YUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica China Co Ltd
Original Assignee
Boehringer Ingelheim Vetmedica China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica China Co Ltd filed Critical Boehringer Ingelheim Vetmedica China Co Ltd
Publication of AU2019237413A1 publication Critical patent/AU2019237413A1/en
Publication of AU2019237413B2 publication Critical patent/AU2019237413B2/en
Application granted granted Critical
Publication of AU2019237413C1 publication Critical patent/AU2019237413C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019237413A 2018-03-19 2019-03-14 Recombinant virus capable of stably expressing target proteins Active AU2019237413C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018079410 2018-03-19
CNPCT/CN2018/079410 2018-03-19
PCT/CN2019/078057 WO2019179345A1 (en) 2018-03-19 2019-03-14 Recombinant virus capable of stably expressing target proteins

Publications (3)

Publication Number Publication Date
AU2019237413A1 AU2019237413A1 (en) 2020-09-24
AU2019237413B2 AU2019237413B2 (en) 2025-08-07
AU2019237413C1 true AU2019237413C1 (en) 2025-10-30

Family

ID=67988104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019237413A Active AU2019237413C1 (en) 2018-03-19 2019-03-14 Recombinant virus capable of stably expressing target proteins

Country Status (9)

Country Link
US (1) US11904010B2 (https=)
EP (1) EP3768831A4 (https=)
JP (1) JP7387623B2 (https=)
KR (1) KR102785418B1 (https=)
CN (1) CN111902535B (https=)
AU (1) AU2019237413C1 (https=)
CA (1) CA3094416A1 (https=)
MX (1) MX2020009720A (https=)
WO (1) WO2019179345A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094416A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica (China) Co., Ltd. Recombinant virus capable of stably expressing target proteins
CA3162622A1 (en) * 2019-11-25 2021-06-03 Baylor College Of Medicine Selective expansion of gene-targeted cells
CN112430625B (zh) * 2020-11-23 2022-08-05 武汉枢密脑科学技术有限公司 含有变异猪伪狂犬病病毒gD蛋白基因的重组腺相关病毒转移载体、病毒及其制备和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
MX9206981A (es) * 1991-12-06 1994-08-31 Whitehead Biomedical Inst Vacunas de recombinantes y metodo para producirlas.
GB9927353D0 (en) * 1999-11-19 2000-01-19 Cantab Pharma Res Virus preparation and use
EP2468768A3 (en) * 2005-07-21 2012-10-31 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
CN101444622A (zh) * 2008-06-06 2009-06-03 中国人民解放军军事医学科学院军事兽医研究所 以猪伪狂犬病病毒为载体的日本血吸虫基因重组活疫苗生产工艺及制品
RU2546247C2 (ru) 2013-06-06 2015-04-10 Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") Вакцина против чумы, аденовирусных инфекций, парвовирусного и коронавирусного энтеритов, лептоспироза и бешенства собак
MA42640B1 (fr) * 2015-11-23 2021-06-30 Merial Inc Protéines de fusion de dmdv et e2 et leurs utilisations
CN107723281B (zh) 2017-09-09 2021-02-12 中国农业科学院哈尔滨兽医研究所 表达猪圆环病毒2型Cap蛋白的重组猪瘟兔化弱毒疫苗株及其应用
EA202092164A1 (ru) * 2018-03-19 2021-02-10 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv с инактивированным ul18 и/или ul8
CA3094416A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica (China) Co., Ltd. Recombinant virus capable of stably expressing target proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBINSON L. ET AL: "Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines", VETERINARY MEDICINE, vol. 63, 1 June 2016 (2016-06-01), pages 30 - 41, XP055860094, ISSN: 1865-1674, DOI: 10.1111/tbed.12521 *

Also Published As

Publication number Publication date
US11904010B2 (en) 2024-02-20
CN111902535A (zh) 2020-11-06
EP3768831A4 (en) 2022-01-05
MX2020009720A (es) 2021-01-08
AU2019237413B2 (en) 2025-08-07
AU2019237413A1 (en) 2020-09-24
US20210353734A1 (en) 2021-11-18
KR20200135412A (ko) 2020-12-02
CA3094416A1 (en) 2019-09-26
RU2020133457A (ru) 2022-04-19
CN111902535B (zh) 2024-08-27
WO2019179345A1 (en) 2019-09-26
EP3768831A1 (en) 2021-01-27
KR102785418B1 (ko) 2025-03-26
JP7387623B2 (ja) 2023-11-28
JP2021518152A (ja) 2021-08-02

Similar Documents

Publication Publication Date Title
JP6913747B2 (ja) イヌアデノウイルスベクター
US10905758B2 (en) Intranasal vector vaccine against porcine epidemic diarrhea
US10619169B2 (en) EHV insertion site ORF70
AU2019237413C1 (en) Recombinant virus capable of stably expressing target proteins
US11261464B2 (en) Promoters
US11596681B2 (en) EHV insertion site UL43
JP2023012474A (ja) 不活性化ｕｌ１８および／またはｕｌ８を有する新しいｅｈｖ
RU2816428C2 (ru) Рекомбинантный вирус, способный к устойчивой экспрессии белков-мишеней
RU2816428C9 (ru) Рекомбинантный вирус, способный к устойчивой экспрессии белков-мишеней
US11033616B2 (en) Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
EA046680B1 (ru) Новый ehv с инактивированным ul18 и/или ul8
EA044953B1 (ru) Векторы аденовируса собачьих

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 18 JUL 2025

FGA Letters patent sealed or granted (standard patent)